Elana Rosenberg
Ophthalmology · New York, NYNPI 1255639605
Payments from drug & device makers
Across 154 payments — averaging $70.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$6K
- AbbVie$2K
- NEW World Medical,inc.$2K
- Alcon$451
- Sight Sciences, Inc.$240
- Genentech USA, Inc.$150
- plus $381 from 8 others
What the payments were for
- Consulting fees$3,72034%
- Speaking & faculty fees$2,60024%
- Food & beverage$4,55242%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 14 | $6,361 |
| AbbVie(2 entities) | 96 | $1,771 |
| NEW World Medical,inc. | 7 | $1,518 |
| Alcon | 13 | $451 |
| Sight Sciences, Inc. | 6 | $240 |
| Genentech USA, Inc. | 1 | $150 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $130 |
| Aerie Pharmaceuticals, Inc. | 6 | $86 |
| Bausch & Lomb Americas Inc. | 3 | $46 |
| Tarsus Pharmaceuticals, Inc. | 2 | $44 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Amgen | 1 | $20 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| Rayner Intraocular Lenses Limited | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent Trabecular Micro-Bypass Stent System$2,220
- iStent inject W$2,138
- iStent inject Trabecular Micro-Bypass Stent System$1,616
- Ahmed Glaucoma Valve$538
- Kahook Dual Blade$538
- DURYSTA$150
- AcrySof IQ VIVITY$149
- OMNI(R) SURGICAL SYSTEM (US)$148
- Streamline Surgical System$142
- IACCESS$138
- XEN GLAUCOMA TREATMENT SYSTEM$124
- Photrexa$119
- Rocklatan$108
- Rhopressa$108
How this compares
$10,872 in reported general payments places this provider in the 85th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 1,010 | $32,806 |
| MoxifloxacinMoxifloxacin Hcl | 860 | $20,546 |
| LumiganBimatoprost | 37 | $19,799 |
| CombiganBrimonidine Tartrate/Timolol | 33 | $16,111 |
| Alphagan PBrimonidine Tartrate | 61 | $14,277 |
| VyzultaLatanoprostene Bunod | 16 | $9,764 |
| Brimonidine Tartrate | 80 | $7,619 |
| RocklatanNetarsudil Mesylat/Latanoprost | 24 | $7,586 |
| Timolol Maleate | 204 | $7,481 |
| Latanoprost | 741 | $6,120 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 338 | $5,064 |
| ProlensaBromfenac Sodium | 12 | $4,590 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 21 | $2,601 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $2,583 |
| Travoprost | 21 | $2,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $1,771 | $50,187131 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $46 | $9,76416 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $86 | $7,58624 claims |
| AlconSimbrinza | $451 | $2,58313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Douglas JabsNew York$24.3M
- Nathan RadcliffeNew York$2.4M
- Richard SpaideNew York$1.7M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
- Sharon KehNew York$941K
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$704K
- Joshua KimNew York$677K
- Eric RosenbergNew York$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.